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Abstract
Backgrounds: Glomerular diseases, a set of debilitating and complex disease entities, are related to mortality and
morbidity. To gain insight into pathophysiology and novel treatment targets of glomerular disease, various types of
biospecimens linked to deep clinical phenotyping including clinical information, digital pathology, and well-defined
outcomes are required. We provide the rationale and design of the KOrea Renal biobank NEtwoRk System TOward
Next-generation analysis (KORNERSTONE).
Methods: The KORNERSTONE, which has been initiated by Korea Centres for Disease Control and Prevention, is
designed as a multi-centre, prospective cohort study and biobank for glomerular diseases. Clinical data,
questionnaires will be collected at the time of kidney biopsy and subsequently every 1 year after kidney biopsy. All
of the clinical data will be extracted from the electrical health record and automatically uploaded to the web-based
database. High-quality digital pathologies are obtained and connected in the database. Various types of
biospecimens are collected at baseline and during follow-up: serum, urine, buffy coat, stool, glomerular
complementary DNA (cDNA), tubulointerstitial cDNA. All data and biospecimens are processed and stored in a
standardised manner. The primary outcomes are mortality and end-stage renal disease. The secondary outcomes
will be deterioration renal function, remission of proteinuria, cardiovascular events and quality of life.
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Discussion: Ethical approval has been obtained from the institutional review board of each participating centre
and ethics oversight committee. The KORNERSTONE is designed to deliver pioneer insights into glomerular
diseases. The study design allows comprehensive, integrated and high-quality data collection on baseline laboratory
findings, clinical outcomes including administrative data and digital pathologic images. This may provide various
biospecimens and information to many researchers, establish the rationale for future more individualised treatment
strategies for glomerular diseases.
Trial registration: NCT03929887.
Keywords: Nephrology, Pathology, Glomerulonephritis
Background
The prevalences of chronic kidney disease (CKD) and
end-stage renal disease (ESRD) are continuously increas-
ing around the world. Recent evidence indicates that the
number of incident ESRD patients due to glomerular
diseases is increasing [1, 2], and many additional ESRD
cases are expected to have been attributed to glomerular
diseases, considering the cases that have not been
confirmed by kidney biopsy. However, the discovery of
pathognomonic biomarkers and disease-specific therapeutic
targets for glomerular diseases is limited.
To better understand the pathophysiology, biomarkers,
and treatment targets of glomerular diseases and ultimately
to improve clinical outcomes, it is imperative to translate
and integrate research with various types of biospecimen
linked to deep clinical phenotyping, including clinical infor-
mation, self-questionnaires, digital pathology and outcomes
from the electronic health record (EHR) and administrative
data. A significant additional number of kidney disease
cohorts were established through several international
consortiums. The C-PROBE, [3] ERCB cohort [4] with
CKD patients, and Nephrotic Syndrome Study Network
(NEPTUNE) cohort [5] for patients with nephrotic
syndrome were started in approximately 2010, and these
cohorts are relatively small. Recently, large-scale genomics
consortia, including CKDGen [6] and EURenOmics, [7]
have been activated in the United States and Europe. How-
ever, these cohorts are not sufficient to support data for
Asians. To that end, a multicentre prospective cohort based
on deep clinical phenotypes, biospecimens, and digital
pathology has been established in Korea, the ‘KORNER-
STONE’, which is supported by the Korea Centers for
Disease Control and Prevention (KCDC).
The objectives of the KORNERSTONE are as follows: 1)
establish a collaborative, innovative deep clinical phenotype-
based investigational infrastructure to carry out clinical and
translational studies of glomerular disease; 2) perform a
longitudinal observational cohort study of patients with
biopsy-proven glomerular diseases; and 3) gain insight into
the pathophysiology, natural history and novel treatment
targets of glomerular diseases. In the present paper, we
report the KORNERSTONE design and methods in detail.
Methods/design
Ethics statements
The basic protocol of this study was approved by the ethics
committee of each participating centre, including the
institutional review boards of Seoul National University
(1404–117-575), Keimyung University Dongsan Hospital
(DSMC 2019–04–015-001), Chung-Ang University (1942–
005-369), Severance Hospital (2019–0463-001), Boramae
Medical Center (L-2019-126), and Kangwon National
University Hospital (KUNH-2019-05-009). Additionally,
the ethics oversight committee of the KORNERSTONE
reviewed the design and protocols of this study. All of the
ethical issues regarding the plans of the KORNERSTONE
cohort study will be supervised by this committee.
Study design and population
The KORNERSTONE is a prospective multicentre
observational biobank, databank and digital pathology
repository of patients with glomerular disease in Korea
(NCT 03929887 at http://www.clinicaltrials.gov). Nephrol-
ogists working in six clinical centres in the major
university-affiliated hospitals, pathologists, and paediatri-
cians are participating in this study. Among the six clinical
centres, four centres are located in the metropolitan city
of Seoul, one is in the southern area, and the last centre is
in northeastern Korea.
Patients suspected of glomerular diseases who received
kidney biopsy in participating university medical centres
are eligible for inclusion in the KORNERSTONE.
Patients who previously received a kidney transplant will
be excluded. This study will enrol 3000 children (age < 18
years) and adults. Eligible participants will be screened at
the inpatient or outpatient clinic of the department of
nephrology or paediatrics of each participating hospital.
Participants who pass an initial screening and agree to
participate will provide written informed consent during
their visit. Parents of all children, and children themselves
if age more than 6 years, provided written informed con-
sent. Informed consent includes utilization, collection, and
provision of demographics, clinical information, and social
security number for the linkage of administrative data and
biospecimens. When a participant wants to withdraw
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from the KORNERSTONE, all stored biospecimens and
data will be destroyed or deleted. All of the laboratory
data, self-questionnaires and biospecimens will be
collected at the time of kidney biopsy for the baseline
information (Table 1). Patients or the public were not
involved in the design, or conduct, or reporting, or
dissemination plans of our research.
Sample size consideration
Table 2 summarizes the statistical power for time-to-event
analyses (minimum detectable hazard ratio [MDHR]). For
illustration, MDHRs were described for comparisons
between two groups of equal size, which could represent
any subgroups of interest (e.g., genetic risk alleles, treat-
ment exposures, and clinical diagnosis). Clinical outcome
event rates, including ESRD, death and complete remission,
were based on published articles and early observed data in
other glomerular disease cohorts [8–11].
Clinical, patient-oriented outcomes and follow-up
After enrolment, all of the participants will be assessed
for whether they reach clinical endpoints each time they
visit the outpatient clinic. The clinical endpoints of this
study were divided into two categories: 1) deterioration
of clinical outcomes was defined by doubling of serum
Cr or decrease in estimated glomerular filtration rate
(eGFR) by more than 30%, and 2) improvement of
clinical outcomes was defined by the remission of
glomerulonephritis and proteinuria < 0.3 g/day. Other
hard outcomes were defined by ESRD, cardiovascular
events, and death. The patients who have proteinuria <
0.3 g/day at baseline have no improvement in clinical
outcomes.
Whether the enrolled patients reached each clinical
endpoint will be confirmed by the EHR. If the participant
displays deterioration, improvement of clinical outcomes,
ESRD or cardiovascular events, laboratory findings, urin-
alysis, and biospecimens, including serum, plasma, buffy
coat, and urine, will be collected from the participants.
Stools will be collected at baseline only. Additionally, the
same information and biospecimens will be collected from
the participants at least once per year.
In addition, the patient-oriented outcome will be secured
by age-appropriate questionnaires. These outcomes will
include symptoms from the patient’s perspective, functional
status, nutritional status and health-related quality of life.
The questionnaires will be collected every year.
All of the administrative data from Statistics Korea,
Health Insurance Review and Assessment Service (HIRA)
and National Health Insurance Service (NHIS) and ESRD
registry data from the Korean Society of Nephrology will
be linked through social security numbers or birth date.
However, the information will not be stored by the
researchers and will only be used for the collection of
clinical outcome information under the approved proto-
col. The prescribed medication and diagnosis defined by
the 10th revision of the International Statistical Classifica-
tion of Diseases and Related Health Problems (ICD-10)
will be collected by HIRA and NHIS. The mortality and
the cause of death will be obtained from Statistics Korea
data. The reached ESRD outcomes, including dialysis and
kidney transplantation, will be determined using the data
from NHIS and the Korean ESRD registry from the
Korean Society of Nephrology (Fig. 1). For clinical hard
outcomes, including death and ESRD, the EHR of each
participating centre and various administrative data will
be used, so the outcome can be reliably determined even
in the case of patient transfer to another hospital or of
patients who cannot participate this cohort for other
reasons.
Electronic health record and questionnaires
The detailed protocol for clinical data and questionnaire
collection is described in Table 1. The eligible patients
will be evaluated at baseline for demographic informa-
tion, smoking history, chief complaints, and anthropo-
metric information, including height, weight, and blood
pressure. Measurements of the resting blood pressure in
the inpatient setting on the kidney biopsy date using an
electronic sphygmomanometer will be carried out.
We will collect laboratory findings closest to the kidney
biopsy date. Serum creatinine will be measured using an
isotope dilution mass spectrometry (IDMS) traceable
method. The eGFR will be calculated using the Chronic
Kidney Disease Epidemiology Collaboration (CKD-EPI)
equation for adults. In children younger than 18 years, the
creatinine-cystatin C-based CKiD (Chronic Kidney Dis-
ease in Children) equation will be used. Blood laboratory
tests, such as complete blood cell count; chemistry,
including calcium, phosphorus, total protein, and albumin;
lipid panel; electrolyte panel; viral serology, and glomeru-
lar disease-related serology will be conducted. Quantita-
tive tests of proteinuria and albuminuria will also be
carried out. The information on prescribed medication
will include the start and end date of each medication,
doses per der day, and total number of prescription days.
The subjects will complete age-appropriate question-
naires concerning the quality of life using Kidney Disease
and Quality of Life Short Form (KDQOL-SF) version 1.3,
socioeconomic status, educational level, physical activity,
health behaviours, health care facility utilization, and
nutritional status using semi-food frequency question-
naires (semi-FFQs) and a food diary.
Human biospecimen collection, quality control and
standard operating procedure (SOP)
Eight types of biospecimens will be collected: plasma,
serum, buffy coat, genomic DNA, urine, stools, stool
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Table 1 List of clinical information and biospecimens in the KORNERSTONE
























Medications Hypertensive medications O O O O O O O O
Immunosuppressant O O O O O O O O
Questionnaires Health questionnaires (including smoking) O O O O O O O O
KDQOL-SF version 1.3 questionnaires O O O O O O O O
Semi-food frequency questionnaires O O O O O O O O
PedsQL 4.0 Generic Core Scales (Children) O O
Anthropometry Height, weight O O O O O O O
Blood pressure O O O O O O O
Blood laboratory
findings
CBC (white blood cell count, platelet, haemoglobin) O O O O O O O O
Chemistry (calcium, phosphorus, glucose, blood urea
nitrogen, uric acid, total protein, albumin, total
bilirubin, alkaline phosphatase, AST, ALT)
O O O O O O O O
IDMS-traceable Cr, eGFR O O O O O O O O
Lipid panel (total cholesterol, triglyceride, high-density
lipoprotein, low density lipoprotein)
O O O O O O O O
Electrolyte panel (sodium, potassium, chloride) O O O O O O O O
Total CO2 O O O O O O O O
C-reactive protein O O O O O O O O
Serology (HBsAg, HBsAb, Anti-HCV, HIV, VDRL) O
Anti-dsDNA, FANA, FANA titre, ANCA, PR3, MPO O
Complement 3, 4 O
ASO, rheumatoid factor, Cryoglobulin O
Urine laboratory
findings
Random urine protein O O O O O O O O
Random urine microalbumin O O O O O O O O
Random urine creatinine O O O O O O O O
Urinalysis protein O O O O O O O O
Urinalysis RBC O O O O O O O O
Kidney biopsy Biopsy results and images including LM, IF and EM O
Report of diagnosis O
Total number of glomeruli O
Total number of global sclerosis/segmental
sclerosis/crescent
O
Biospecimens Serum/plasma/buffy coat/genomic DNA sample O O O O O O O O
Urine sample O O O O O O O O
Stool sample O
cDNA from glomeruli and tubules in micro-dissected
kidney biopsy tissues
O
CBC complete blood count; KDQOL-SF Kidney Disease-Quality of Life Short Form; PedsQL Pediatric Quality of Life Inventory; AST aspartate aminotransferase; ALT
alanine aminotransferase; HCV hepatitis C virus; HIV human immunodeficiency virus; VDRL veneral disease research laboratory test; FANA fluorescent antinuclear
antibody; MPO myeloperoxidase; ASO antistreptolysin O; RBC red blood cell; LM light microscopy; IF immunofluorescent; EM electron microscopy; IDMS isotope
dilution mass spectrometry; Cr creatinine; eGFR estimated glomerular filtration rate; Y year
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DNA and cDNA from glomeruli and tubules in micro-
dissected kidney biopsy tissues (Table 1). Anonymous
barcodes will be printed and attached to all samples col-
lected. Additionally, registered information, including
the type, quantity, and location of biospecimens, will be
uploaded to the web database. All of the samples will be
subsequently collected regularly according to the stan-
dardized protocol. All of the biospecimens, including
plasma, serum, buffy coat, urine, genomic DNA and
stool DNA, will be stored at the National Biobank of
Korea launched by the KCDC.
Blood will be stored as plasma, serum, buffy coat, and
genomic DNA. From one participant in the KORNER-
STONE, at least one SST tube and two EDTA tubes
with blood (8 cc per tube, total 24 cc), more than 10 cc
of urine, more than 1 g in 2 bottles of stool, stool DNA,
and at least one core of kidney biopsy tissue will be
collected. Blood and urine samples will be centrifuged
for 10 min and will be distributed in cryotubes. Serum
and plasma will be stored in a liquid nitrogen freezer (−
196 °C), and other types of biospecimens will be stored
in a deep freezer (− 80 °C) (Table 3).
For quality control of biospecimens, 7-digit Standard PRE-
analytical Code (SPREC), which encodes pre-processing
information of biospecimens, will be assigned for each blood
and urine sample [12]. Serum and plasma samples will be
visually checked for haemolysis. The protocol for each
biospecimen is described in the supplementary section.
Digital pathology repository
Kidney biopsy materials from enrolled patients, includ-
ing glass slides scanned into high-resolution whole slide
images, both stained and non-stained; digital images of









proteinuria (< 0.3 g/day)b
0.63–0.97 1.14–1.17
Abbreviations: MDHR minimum detectable hazard ratio; ESRD end-stage
renal disease
aMDHR is based on the following assumptions: patient follow-up time of 5
years (ESRD and death); a loss of follow-up rate during 5 years hypothesized
total of 10%; 80% power, alpha = 0.05
bGroup sizes for time to complete remission of proteinuria excluded one-third
of the group that was in remission at enrolment
Fig. 1 Overall schemes of the KORNERSTONE. KORNERSTONE, Korea Glomerular disease Biobank Network; gDNA, genomic DNA; OPD, outpatient; EHR,
electronic health record; LM, light microscopy; IF, immunofluorescence; EM, electron microscopy; QC, quality control; VPN, virtual private network
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immunofluorescence and electron-micrographs; and
pathologic reports from each centre will be collected
and uploaded into the KORNERSTONE Digital Path-
ology Repository (Fig. 2). A digitizing pathology work-
flow was developed (HuminTec, Suwon, Korea). All of
the glass slides will be scanned by Aperio AT2 (Leica
Biosystems, Germany, Wetzlar). These digital image files
will be stored centrally in the KreoNET server (Seoul
National University Hospital, Seoul, Korea). From this
system, high-quality pathology images can be acquired
in a user-friendly manner and readily shared with clini-
cians. Before the data are sent to the central server, the
study number is allocated to the pathologic images to
enable the linking of pathologic data with clinical data
and biospecimens. All of these images will be connected
in the web-based database.
Web-based database infrastructure for integration of all
information
The overall schemes of the KORNERSTONE are described
in Fig. 1. All of the laboratory findings, prescribed medica-
tions, and results of pathology will be extracted from the
EHR through the clinical data warehouse as Excel or csv
files to reduce participants’ burden. The extracted files,
including laboratory and anthropometric results from each
hospital, are automatically converted into a common case-
report form through the macro algorithms. When the
converted case-report form is uploaded to the database,
different variables for each hospital can be standardized to
match internal variables in the web database. The electronic
web-based database management system was developed
(Binarylab, Seoul, Korea). Additionally, the automatic ques-
tionnaire response system was developed for this cohort
(ONCE Interactive, Seoul, Korea). Through this system, all
questionnaires will be implemented using a tablet to allow
patients to respond directly, and all responses are automat-
ically stored in the web-based database.
Researchers or clinical research coordinators who want
to upload or download data in the web-based database
management system should log in only using a virtual
private network (VPN) system to protect personal infor-
mation. VPN accounts are managed by the principal
investigator and clinical research associate and are only
accessible by KORNERSTONE authorized staff.
Governance and dissemination policy of the
KORNERSTONE
The purpose of the KORNERSTONE is to provide a foun-
dation for the discovery of new prediction markers of
glomerular diseases and the promotion of the utilization
of human-derived resources within the legal and ethical
regulations. Given the guidelines of future activities, the
creation of governance in the KORNERSTONE is crucial.
All collection of biospecimens and information and
clinical and research activities will be supervised by the
independent governance of KORNERSTONE (Fig. 3).
Researchers who want to use resources from the KOR-
NERSTONE should contact initially the KCDC (biobank@
korea.kr). All of the collected data and biospecimens of the
KORNERSTONE can be used only for future studies that
are within the perspective of scientific objectives of the
KORNERSTONE and that are approved by the Dissemin-
ation and Advisory Committee (Fig. 4). Any researchers
can submit a study proposal including study objectives and
the type of data and biospecimens required to the Dissem-
ination and Advisory Committee of the KORNERSTONE.
If a study proposal is approved, a new VPN account will be
given to the approved researcher. All of the data will not be
Table 3 Overview of stored samples per participant in the KORNERSTONE
Biospecimen Stored vial Volume and amount Storage temperature
Serum 1.8 ml cryogenic vial Adults: 300 μl × 5 vials ≤ − 196 °C
Children: 100 μl × 4 vials
Plasma 1.8 ml cryogenic vial Adults: 300 μl × 5 vials ≤ − 196 °C
Children: 100 μl × 4 vials
Genomic DNA 1.7 ml microcentrifuge tube Adults: Total more than 100 μg, 3 vials ≤ − 80 °C
Children: Total 30 μg, 2 vials
Urine 1.8 ml cryogenic vial Adults: 1 ml × 5 vials ≤ − 80 °C
Children: 200 μl × 5 vial
Buffy coat 1.8 ml cryogenic vial Adults: 200 μl × 2 vials ≤ − 80 °C
Children: 100 μl × 2 vials
Stool DNA 1.7 ml microcentrifuge tube 100 μl, 1 vial ≤ − 80 °C
Stool 30 ml container 1 g, 2 bottles ≤ − 80 °C
Microdissected glomerulus (cDNA) 1.7 ml microcentrifuge tube Total 70 ng × 2 vials ≤ − 80 °C
Microdissected tubulointerstitium (cDNA) 1.7 ml microcentrifuge tube Total 100 ng × 2 vials ≤ − 80 °C
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Fig. 2 Digital pathology repository. LM, light microscopy; IF, immunofluorescence; EM, electron microscopy
Fig. 3 KORNERSTONE governance structure. KORNERSTONE, Korea Glomerular disease Biobank Network; DB, database; KCDC, Korea Centers for
Disease Control and Prevention
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accessible, as only information and biospecimens from
those patients who meet the inclusion criteria in the
approved protocol will be provided to the investigators.
The results of each study will be reviewed by the Scientific
Assessment Committee of KORNERSTONE and will be
published after peer review.
Discussion
Glomerular diseases, a set of debilitating and complex clin-
ical disease entities affecting individuals of all ages, are asso-
ciated with significant mortality and morbidity, including
hospitalization and ESRD. Although there are many ad-
vances in understanding novel genetic and environmental
factors affecting the pathophysiology of various glomerular
diseases, there is an insufficient number of basic and trans-
lational studies that integrate clinical, pathological, and
genetic information. The KORNERSTONE, a prospective
cohort study with various biospecimens funded by the
KCDC, was established for supporting and providing high-
quality clinical information and biospecimens based on
deep clinical phenotypes of glomerular diseases.
The presentation and prognosis of each glomerular
disease covers a wide spectrum even in the same diagno-
sis, and it is challenging to define each glomerular dis-
ease using only clinical descriptions [13]. This fact might
be due to the classification of glomerular disease based
on histopathology rather than an understanding of the
molecular, genetic or environmental underpinnings of
these diseases; thus, kidney biopsy is essential for a defini-
tive diagnosis. However, a kidney biopsy is an invasive,
burdensome procedure for patients, so multiple biopsy
tissue collections are onerous. Misclassification of the
subgrouping of glomerular diseases due to the limited
reproducibility of pathologic diagnosis is another barrier
for studying glomerular disease [14, 15]. While patho-
logical review is important in diagnosis, progression or
remission is identified by clinical phenotypes, including
proteinuria or eGFR. Considering the chronic pathway of
glomerular diseases, a deep clinical phenotype linked seri-
ally to obtained biospecimens will be a complementary
substitute for the gap between pathology and clinical
phenotype regarding time and precision. Thus, in-depth
knowledge of each of these glomerular diseases is needed
to provide effective care for the patients. Based on this
background, many researchers agreed that the practice of
personalized and precision medicine is necessary for this
disease entity [16]. Precision medicine proposes the devel-
opment of new disease definitions achieved by a multi-
layered multi-omics analysis of the disease course [17].
These kinds of studies provide comprehensive information
along with the genotype-phenotype continuum, and it is
inevitable to establish a systemic biobank that includes
well-organized clinical data, evaluation of environmental
factors and collection of biospecimens. From this point of
view, several prospective observational cohort studies for
glomerulonephritis were established: the Toronto Glomer-
ulonephritis Registry, [18, 19] the University of North
Carolina Glomerular Disease Collaborative Network,
[20, 21] PodoNet, [22, 23], the British Columbia
Glomerulonephritis Registry [24], Cure Glomerulone-
phropathy (CureGN), [25] and the NEPTUNE [5]. In
addition, regarding biobanks, the Biobank for the
Molecular Classification of Kidney Disease (BMCKD)
is underway in Canada [26].
Pathology is a crucial test for the diagnosis and evaluation
of prognosis for glomerular diseases. Expertise, abundant
Fig. 4 Application and dissemination process of the KORNERSTONE. KORNERSTONE, Korea Glomerular disease Biobank Network; KCDC, Korea
Centers for Disease Control and Prevention
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experience and reproducibility are critical to exact
diagnostic accuracy. A digital pathology repository will be
an essential tool for integrating clinical and pathological
information together, and this system was introduced in
this study. Through this digital pathology, misclassification
for a subgroup of glomerular diseases can be reevaluated
by many different pathologists and nephrologists.
Additionally, with the advancement of high-resolution
scanners, computing power, faster networks and file com-
pression technology to scan glass slides, virtual slides with
the digitalization of whole pathologic images have been
achieved [27]. The introduction of digital pathology allows
clinicians and pathologists to efficiently discuss various
pathologic findings, not only text-based information. In
addition, the reproducibility of diagnosis has been im-
proved. Artificial intelligence that was utilized mainly in
radiology and cardiology has been extended to pathology
through digital glass slides. Advances in digital pathology
and computer-aided diagnostic tools have made it possible
for pathologists and nephrologists to identify unique im-
aging markers related to specific diseases, which leads to
improvement of early detection and selection of effective
treatment targets [28]. In line with this background, the
KORNERSTONE will integrate digital pathologic images.
The KORNERSTONE will collect data from all pa-
tients undergoing kidney biopsy due to suspected
glomerular disease, which is not limited to a specific
diagnosis. Therefore, this cohort will be composed of
more diverse diseases, including minimal change disease,
focal segmental glomerulosclerosis, membranous nephrop-
athy, membranoproliferative glomerulonephritis, crescentic
glomerulonephritis, IgA nephropathy, and lupus nephritis,
than the CureGN [25] and NEPTUNE cohorts [5]. Most of
the glomerular disease cohorts have been constructed in
Western countries. However, the epidemiology of glomeru-
lar diseases is different from that in Western populations,
[11, 29] so the KORNERSTONE will be a good resource
for providing Asian population data and revealing regional
variation in glomerular diseases. Additionally, several stud-
ies reported that environmental factors and the microbiome
can affect the development and prognosis of glomerular
diseases, especially in IgA nephropathy [30–32]. The NEP-
TUNE cohort collected only quality of life and self-reported
health data through questionnaires as patient-centred out-
comes, and there were no surveys on influential factors
other than outcomes. In the KORNERSTONE, environ-
mental factors, including dietary data will be collected using
semi-FFQ and food diaries, and stool samples will be gath-
ered for further analysis of the microbiome. This approach
will allow many researchers to evaluate in additional detail
the impact of environmental factors on glomerular diseases.
One of the strong points of this cohort, administrative
data from various government institutions, including
HIRA, NHIS, Statistics Korea and the ESRD registry,
linked by social security number will be collected. In
particular, Korea achieved nationwide health insurance
covering its whole population in 1989 [33], and all med-
ical billing data for the total Korean population is in-
cluded in NHIS and HIRA data. Researchers can achieve
full inspection of clinical hard outcomes. Through this
method, it is possible to identify all of the clinical out-
comes even when the outcomes occur in other hospitals
and for patients not enrolled in the clinical centre. Last,
after the enrolment, each time the participant visits the
hospital, we will check whether they reached the clinical
outcomes. Even if there is no event, we collect clinical
data and biospecimens every year. Through this follow-
up plan, all of the clinical outcomes will be confirmed as
soon as possible, and small differences will be detected
that are clinically meaningful. Importantly, we can
collect diverse and serial biospecimens. In this regard, it
is possible to perform further analysis for risk factors of
a rapid deterioration of renal function and refine the
natural course of each glomerular disease.
In conclusion, we describe the objectives and clinical
protocol for the KORNERSTONE. As the first large-scale
glomerulonephropathy cohort study with the integration
of clinical data, biospecimens and digital pathologic im-
ages in Korea, the KORNERSTONE will help to clarify the
natural course, complication profiles, and novel treatment
targets of the Asian population with glomerular disease.
We expect that the KORNERSTONE will promote
collaborative research for treatment targets for improving
clinical and patient-oriented outcomes in patients with
glomerular disease.
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